Search

Displaying results 1841 - 1850 of 4359 in total
  1. Drug

    Temsirolimus

    go.drugbank.com/drugs/DB06287
    ApprovedInvestigational

    Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.

  2. Drug

    Cetirizine

    go.drugbank.com/drugs/DB00341
    ApprovedInvestigational

    Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal

    Products: CETIRIZINA DOC GENERICI, CETIRIZINA MYLAN GENERICS
  3. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive

  4. Drug

    Mogamulizumab

    go.drugbank.com/drugs/DB12498
    ApprovedInvestigational

    Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF

  5. Drug

    Blonanserin

    go.drugbank.com/drugs/DB09223
    Investigational

    It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. … As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics.

  6. Drug

    Tegafur

    go.drugbank.com/drugs/DB09256
    ApprovedInvestigational

    Tegafur (INN, BAN, USAN) is a prodrug of [DB00544] (5-FU), an antineoplastic agent used as the treatment of various cancers such as advanced gastric and colorectal cancers. … It is a pyrimidine analogue used in combination therapies as an active chemotherapeutic agent in conjunction with [DB09257] and [DB03209], or along with [DB00544] as [DB09327].

  7. Drug

    SCB-2019

    go.drugbank.com/drugs/DB15805
    Investigational

    The vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd.. … As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908) to test the safety and immunogenicity of the vaccine.

  8. Drug

    Lincomycin

    go.drugbank.com/drugs/DB01627
    ApprovedInvestigationalVet approved

    Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium Streptomyces lincolnensis in Lincoln, Nebraska. Clinical use of lincomycin has largely been superseded by its semisynthetic derivative clindamycin due to its h...

  9. Drug

    Dorzolamide

    go.drugbank.com/drugs/DB00869
    ApprovedInvestigational

    [A1304] First marketed in 1995,[A190624] dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt [L11377] or in combination with [timolol] as Cosopt PF.[L11380]

    Mixtures: DORZOLAMIDE E TIMOLOLO MYLAN GENERICS, DORZOLAMIDE E TIMOLOLO MYLAN GENERICSProducts: DORZOLAMIDE MYLAN GENERICS
  10. Drug

    Acyclovir

    go.drugbank.com/drugs/DB00787
    ApprovedInvestigational

    [L7303,L7315,L7318,L7321,L7324,L7327] Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young as 6 years old.

    Products: ACICLOVIR DOC GENERICI, ACICLOVIR MYLAN GENERICS